Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2026-07-12
Based on 378 first isolates · MED-B · Febrile UTI / pyelonephritis · 2025-07-13 → 2026-07-12
Internal medicine B
Per-organism detail: MED-B urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
ceftriaxone 80 % (76 %–84 %)
Not covered: Enterococcus faecalis (8 %), Pseudomonas aeruginosa (5 %), Staphylococcus aureus (2 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
meropenem MEM
trend · Escherichia coli reserve
87 %
80 %
n = 30
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
83 %
80 %
n = 30
nitrofurantoin NIT
trend · Escherichia coli not for this site
83 %
87 %
n = 30
ceftriaxone CRO
trend · Escherichia coli
80 %
70 %
n = 30
mecillinam MEC
trend · Escherichia coli not for this site
79 %
73 %
n = 30
ciprofloxacin CIP
trend · Escherichia coli
78 %
63 %
n = 30
74 %
63 %
n = 30
trimethoprim TMP
trend · Escherichia coli not for this site
70 %
73 %
n = 30
46 %
43 %
n = 30
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
11 %
13 %
n = 30
5 %
7 %
n = 30
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
2 %
3 %
n = 30

Most likely organisms for this profile

Escherichia coli
59 %
Klebsiella pneumoniae
10 %
Enterococcus faecalis
8 %
Proteus mirabilis
7 %
Citrobacter freundii
5 %
Pseudomonas aeruginosa
5 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.